Last reviewed · How we verify
Anti-HER2 CAR-T cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Anti-HER2 CAR-T cells (Anti-HER2 CAR-T cells) — UTC Therapeutics Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Anti-HER2 CAR-T cells TARGET | Anti-HER2 CAR-T cells | UTC Therapeutics Inc. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Anti-HER2 CAR-T cells CI watch — RSS
- Anti-HER2 CAR-T cells CI watch — Atom
- Anti-HER2 CAR-T cells CI watch — JSON
- Anti-HER2 CAR-T cells alone — RSS
Cite this brief
Drug Landscape (2026). Anti-HER2 CAR-T cells — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-her2-car-t-cells. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab